This pathway influences the immune landscape by modulating the expression of immune-related genes, including those involved in T cell trafficking and PD-L1 expression on tumor cells.401 Combining MAPK/ERK pathway inhibitors with ICIs is an area of active investigation that holds promise in overcoming resistance to immunotherapy.402. This evidence concerns the gene CD274 and neoplasm.